Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31469677 | 0.79 | NOS3 (0.38) | PDE1APDE1BPDE1CMERTKKDM4E | |
| SCHEMBL31469631 | 0.79 | ABL1 (0.36) | PDE1APDE1BPDE1CMERTKKDM4E | |
| SCHEMBL3608704 | 0.79 | PIK3CA (0.35) | MERTK | |
| SCHEMBL24287321 | 0.78 | FPR1 (0.38) | PDE1APDE1BPDE1CMERTKKDM4E | |
| SCHEMBL20117217 | 0.77 | ADORA2A (0.39) | KDM4ENT5E | |
| SCHEMBL5353111 | 0.76 | MTOR (0.39) | PDE1APDE1BPDE1CMERTKKDM4E | |
| SCHEMBL5360329 | 0.74 | KDM4E (0.38) | PDE1APDE1BPDE1CMERTKKDM4E | |
| SCHEMBL5357228 | 0.72 | NT5E (0.34) | PDE1APDE1BPDE1CNT5E | |
| SCHEMBL20688200 | 0.70 | L3MBTL1 (0.50) | PDE1APDE1BPDE1CKDM4EGRM4 | |
| SCHEMBL17232694 | 0.69 | GRM4 (0.43) | PDE1APDE1BPDE1CGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | PDE1A 17/4885PDE1B 18/4885PDE1C 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.